Alzheimer's and Dementia Guidelines and Tables.

Q3 Medicine
Psychopharmacology bulletin Pub Date : 2023-07-12
Lon S Schneider
{"title":"Alzheimer's and Dementia Guidelines and Tables.","authors":"Lon S Schneider","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Introduction The purpose of this guide is to provide convenient and useful information on about Alzheimer's disease and dementias of late life. The information includes selected facts, diagnostic criteria tables, descriptions of selected tests and screens, guidelines, clinical pharmacological data and references. This guide is divided into several sections: Background factsDiagnostic aids and criteria for dementia diagnosesMedications used for Alzheimer's disease and dementia Basic information on marketed treatments is provided although the treatment may not be FDA approved for this use. Approved cholinesterase inhibitors, memantine, and monoclonal antibodies are listed. No treatment is recommended or endorsed, however. This guide does not address the evidence base for the efficacy of the treatments listed. <i>Caveats</i>: Except for treatments above, discussions of medications for people with dementia nearly always involve off label use. For example, antidepressants and antipsychotics are indicated in the FDA-approved prescribing information for major depression and schizophrenia, and not for depressive symptoms or the delusions or hallucinations occurring within the context of dementia with two exceptions. In these instances, the doses listed are for reference only and should not be considered as recommendations or appropriate use. Physicians should consult the product package labeling for any drug mentioned.</p>","PeriodicalId":21069,"journal":{"name":"Psychopharmacology bulletin","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363282/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychopharmacology bulletin","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction The purpose of this guide is to provide convenient and useful information on about Alzheimer's disease and dementias of late life. The information includes selected facts, diagnostic criteria tables, descriptions of selected tests and screens, guidelines, clinical pharmacological data and references. This guide is divided into several sections: Background factsDiagnostic aids and criteria for dementia diagnosesMedications used for Alzheimer's disease and dementia Basic information on marketed treatments is provided although the treatment may not be FDA approved for this use. Approved cholinesterase inhibitors, memantine, and monoclonal antibodies are listed. No treatment is recommended or endorsed, however. This guide does not address the evidence base for the efficacy of the treatments listed. Caveats: Except for treatments above, discussions of medications for people with dementia nearly always involve off label use. For example, antidepressants and antipsychotics are indicated in the FDA-approved prescribing information for major depression and schizophrenia, and not for depressive symptoms or the delusions or hallucinations occurring within the context of dementia with two exceptions. In these instances, the doses listed are for reference only and should not be considered as recommendations or appropriate use. Physicians should consult the product package labeling for any drug mentioned.

阿尔茨海默氏症和痴呆症指南和表格。
导言 本指南旨在提供有关阿尔茨海默病和晚年痴呆症的便捷实用信息。这些信息包括部分事实、诊断标准表、部分测试和筛查的说明、指南、临床药理数据和参考文献。本指南分为几个部分:背景事实诊断辅助工具和痴呆症诊断标准用于治疗阿尔茨海默病和痴呆症的药物 本指南提供了有关市场上销售的治疗方法的基本信息,尽管这些治疗方法可能尚未获得美国食品及药物管理局的批准。其中列出了已获批准的胆碱酯酶抑制剂、美金刚和单克隆抗体。但没有推荐或认可任何治疗方法。本指南不涉及所列疗法疗效的证据基础。注意事项:除上述治疗方法外,有关痴呆症患者用药的讨论几乎总是涉及标签外用药。例如,FDA 批准的处方信息中,抗抑郁剂和抗精神病药适用于重度抑郁症和精神分裂症,而不适用于抑郁症状或痴呆症中出现的妄想或幻觉,只有两种情况例外。在这些情况下,所列剂量仅供参考,不应被视为建议或适当用量。医生应查阅所提及药物的产品包装标签。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Psychopharmacology bulletin
Psychopharmacology bulletin PHARMACOLOGY & PHARMACY-PSYCHIATRY
CiteScore
2.70
自引率
0.00%
发文量
32
期刊介绍: Information not localized
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信